title: Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies.
abstract: BACKGROUND
  Neutralizing antibodies (NAB) to interferon beta (IFNbeta) occur in about one-third of MS patients treated with IFNbeta-1b and there is an association with a loss of clinical and MRI efficacy. However, there are no data regarding the bioavailability of IFNbeta-1b in patients with and without NAB.
  
  
  METHODS
  The authors measured MxA in whole blood by ELISA, and serum-binding antibodies (SBA) by Western blot and ELISA in 134 samples of MS patients on IFNbeta-1b and 54 control subjects, and correlated the MxA levels and SBA titers with the NAB titer.
  
  
  RESULTS
  In the IFNbeta group 84 samples were NAB negative, 21 were NAB positive (i.e., titer of > or =20), and 29 had detectable NAB (i.e., titer between 10 and 20). The median MxA concentration in NAB-negative patients was 4.09 ng/10(5) peripheral blood leukocytes (PBL), 2.37 ng/10(5) PBL in samples with detectable NAB, 0.36 ng/10(5) PBL in NAB-positive samples, and 0.27 ng/10(5) PBL in control subjects. There was no significant difference between NAB-positive samples and control subjects, otherwise the groups differed significantly from each other. SBA occurred in 49% of NAB-negative samples, in 79% of samples with detectable NAB, and in all NAB-positive samples. With regard to the SBA titer, all groups differed significantly from each other. In none of the control samples were SBA detected.
  
  
  CONCLUSIONS
  The conversion of SBA into NAB depends to some degree on the SBA titer, but other mechanisms may be involved. Once NAB have developed, the bioavailability of IFNbeta as measured by MxA is completely inhibited.
authors.affiliation: Department of Neurology, University of Innsbruck, Austria.
authors.forename: F
authors.initials: F
authors.lastname: Deisenhammer
authors.forename: M
authors.initials: M
authors.lastname: Reindl
authors.forename: J
authors.initials: J
authors.lastname: Harvey
authors.forename: T
authors.initials: T
authors.lastname: Gasse
authors.forename: E
authors.initials: E
authors.lastname: Dilitz
authors.forename: T
authors.initials: T
authors.lastname: Berger
mesh_terms: D000906:Antibodies / Q000097:blood; D001682:Biological Availability; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000097:blood / Q000276:immunology* / Q000378:metabolism*; D009103:Multiple Sclerosis / Q000097:blood / Q000276:immunology* / Q000378:metabolism*; D009500:Neutralization Tests
chemical_list: D000906:Antibodies; D000068576:Interferon beta-1b; D016899:Interferon-beta; D000068556:Interferon beta-1a